Ignite Creation Date:
2024-05-06 @ 3:24 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04628572
Status:
COMPLETED
Last Update Posted:
2023-01-23
First Post:
2020-10-07
Brief Title:
Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Retrospective Analysis to Characterize the Real World Use Patterns Efficacy and Safety of Ceftazidime-avibactam in the Management of Gram Negative Infections
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective of this non-interventional retrospective study is to describe the general treatment patterns effectiveness and safety of ceftazidime-avibactam in real-world settings in India Eligible patients would be adults who have been treated with 48 hours of ceftazidime-avibactam in routine practice from 01 June 2019 to 01 April 2020 Data of 500 patients will be collected through the abstraction of hospital medical records electronic if available or through the individual patient medical record in case electronic records are not available
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None